Veracyte, Inc.
C2i Genomics provides an innovative ctDNA MRD solution for personalized cancer detection and monitoring. C2i’s whole-genome technology delivers ultra-high sensitivity with significantly reduced lab operation complexity, eliminates the need to develop a patient-specific assay, and enables earlier detection of cancer recurrence to inform better treatment decisions and improve outcomes.